Key result
Aliskiren, a novel direct renin inhibitor, has been shown to be efficacious in hypertensive patients at once-daily oral dosing with favorable pharmacokinetics and potential end-organ protection.
Aliskiren represents a novel class of direct renin inhibitors that effectively suppresses the renin-angiotensin system for the treatment of hypertension.
Answers are grounded in this paper and cite their sources.
Aliskiren may support once-daily dosing in hypertension; leaves open confirmation of end-organ protection in outcome trials.
The suppression of the renin-angiotensin system by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been proven in many studies to treat hypertension and reduce cardiovascular events; however, reducing angiotensin I receptor stimulation results in the loss of the negative-feedback signal, leading to increased plasma renin activity. Numerous direct renin inhibitors were synthesized, but abandoned owing to low potency, poor bioavailability and short half-life. Aliskiren, a direct renin inhibitor of a novel structural class, inhibits the activity of the renin produced and, thus, its capacity to form angiotensin I, as measured by plasma renin activity. Aliskiren has been recently shown to be efficacious in hypertensive patients at once-daily oral dosing with favorable pharmacokinetics and the potential to improve end-organ protection.
No takes yet. Share an insight, caveat, or question.
Üresin et al. (2007) conducted a review in Hypertension. Aliskiren was evaluated. Aliskiren, a novel direct renin inhibitor, has been shown to be efficacious in hypertensive patients at once-daily oral dosing with favorable pharmacokinetics and potential end-organ protection.
Synapse has enriched 10 related papers. Consider them for comparative context: